The day at a glance · 3 min read
Mood · Mixed
+15
Sentiment, −100 to +100
Merck YTD gain
42%+42%
Merck share price
$148.05
AbbVie Q3 revenue
$17.4B
Key driverBig Pharma pipeline progress and managed care restructuring offset MedTech antitrust headwinds
Daily briefHealthcare· Money365.Market AI ·

Merck Pipeline, Intuitive Settlement, UnitedHealth Exits

Merck MASH data lifts shares; Intuitive takes $450M antitrust charge; UnitedHealth withdraws Medicare in 140 counties and Wyoming

Big Pharma & Biotech

Bullish

AbbVie FY26 guidance

$67.8B
01MRK
Merck (MRK) has delivered a 42% share price gain since January as the company works to defeat the patent cliff, with shares trading at $148.05 following recent pipeline developments. The company reported Phase 2b data showing its investigational GLP-1 and glucagon co-agonist efinopegdutide achieved statistically significant MASH resolution without fibrosis worsening, fueling fresh investor interest. The stock has posted a 90-day share price return of 11.38% and a year-to-date gain of 39.08%, with a one-year total shareholder return of 67.56%. Analysts have noted concerns around pricing pressure and the coming Keytruda patent expiry, though the growing late-stage pipeline and U.S. manufacturing plans have supported the valuation.
02ABBV
AbbVie (ABBV) raised its full-year 2026 revenue guidance to approximately $67.8 billion and lifted its dividend after reporting third-quarter sales of $17.4 billion and net income of $4.2 billion. The stock has delivered a one-month gain of 6.1% and a three-month share price return of 17.3%, with total shareholder return of 38.1% over one year. The raised guidance, pipeline updates, and dividend increase have contributed to building momentum around the shares.
03EXEL
Exelixis (EXEL) is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, according to Chief Strategy Officer Andrew Peters speaking at a conference discussion. An FDA decision on the drug is approaching as the company positions zanza as a key growth driver.

MedTech & Devices

Neutral

ISRG revenue growth

22%+22%

ISRG settlement charge

$450M

ISRG 90-day return

12.15%+12.15%

ISRG fair value revised

$486.57
01ISRG▼ -2.28%
Intuitive Surgical (ISRG) reported quarterly results showing 22% revenue growth, rising use of its da Vinci 5 and Ion systems, and a $450 million antitrust settlement charge that contributed to choppy share price reaction. The stock is up 12.15% over the past 90 days and 6.15% over the past 30 days, yet down 19.92% on a year-to-date basis, while the three-year total shareholder return of 54.32% points to a stronger longer-run record. Analysts have revised the fair value estimate from approximately $476.34 to roughly $486.57 per share following Q3 results, balancing upbeat system placements and procedure growth against concerns about U.S. volume deceleration and higher expectations already reflected in the stock.
02TMO
Thermo Fisher Scientific (TMO) is emerging as a key supplier in the global cell sheet-based gene therapy market, which is gaining attention in regenerative medicine in 2026. Sector milestones in cell sheet-based therapies for tissue repair and organ regeneration have highlighted the company's tools, platforms, and services used by developers in this field, extending the business further into advanced gene and cell therapy applications.

Health Insurance & Managed Care

Bearish

Members affected

~390K
01UNH▲ +1.89%
UnitedHealth Group (UNH) plans to discontinue some UnitedHealthcare Medicare Advantage products across 140 counties for the 2027 plan year and will fully exit Medicare coverage in Wyoming in 2027, withdrawing both Medicare Advantage and Medicare Part D plans. Approximately 390,000 UnitedHealthcare Medicare members are expected to be affected by these county and state-level plan exits in 2027. The pullback represents a significant restructuring of the company's Medicare Advantage footprint as the insurer adjusts its geographic presence and product mix.

FDA & Regulation

Bullish
BAYRY
01
Bayer has gained FDA approval for Sunharbo, the first Factor XIa inhibitor approved worldwide, for secondary stroke risk reduction, opening new growth opportunities in stroke prevention. The approval represents a novel mechanism of action entering the anticoagulation market and positions Bayer to compete in the secondary stroke prevention category.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy